Regeneron says monoclonal antibodies inhibit Kovid-19 in studies

REggeron said on Tuesday that its monoclonal antibody cocktail prevented Clind-19 in a clinical trial.

The news released via a press release mirrored Eli Lilly’s similar news last week that her monoclonal antibodies prevented the symptomatic Kovid-19 infection in nursing homes.

Results represent 400 volunteers prior to the study, run by the National Institute of Allergy and Infectious Diseases (NIAID), and continue to recruit patients. The volunteers were at high risk of infection because they lived in the same house as the Kovid-19 patient. Half of the patients received a placebo, and the other half received 1.2 g of cacirvimab and imdevimab, antibodies to Regeneron.


While eight of the 223 patients in the placebo group developed Kovid’s symptoms and tested positive for the virus, none of the 186 patients receiving antibodies did. Volunteers receiving antibodies were also less likely to be asymptomatic carriers of SARS-CoV-2 virus, which causes Kovid-19. Twenty-three volunteers in the placebo group tested positive for the virus, a decrease of 50%, compared to 10 in the antibody group.

It also revealed that among volunteers who received antibodies, the infection was less severe than those who did not. In the placebo group, infected volunteers had an average 100-fold higher peak viral load. Infection in the antibody group did not last more than a week, while 40% of the infections in the placebo group lasted for three to four weeks.


Adverse events were less common among those receiving reversible cocktails, with 18% in the reversible group and 12% in the reflex group. This was a result of the negative effects of the virus. Two percent of people in both groups had an injection site response.

Regeneron’s Chief Scientific Officer George Yancopoulos said in a statement that even with the available vaccines, antibodies would help break the chain of infection, and could prove useful for individuals who are unable to vaccinate or are unable to vaccinate. Huh.

Resenarone was able to prepare antibodies so that it could be given as an injection rather than intravenously. This would make antibodies much easier to deliver to health care workers.

The results have not been peer-reviewed or published in an academic journal.

Leave a Reply

Your email address will not be published.